share_log

Bristol-Myers Squibb | CORRESP: CORRESP

Bristol-Myers Squibb | CORRESP: CORRESP

施貴寶 | CORRESP：信函
SEC announcement ·  02/17 05:33
牛牛AI助理已提取核心訊息
Bristol-Myers Squibb Company (BMS) has responded to a comment letter from the U.S. Securities and Exchange Commission (SEC) regarding its tender offer statement for RayzeBio, Inc., initially filed on January 25, 2024. The SEC's letter, dated February 14, 2024, raised concerns about BMS's financing plans, the conditions of the offer, and the acceptance of tenders from shareholders in compliance with jurisdictional laws. BMS, along with its wholly owned subsidiary Rudolph Merger Sub Inc., has filed an amendment to the tender offer statement, addressing the SEC's comments and confirming their intention to comply with Commission rules and regulations. The amendment includes revised disclosures about the source and amount of funds, the conditions to the offer, and the acceptance of tenders from shareholders. BMS has assured the SEC that it will promptly inform RayzeBio stockholders of any developments that may affect the satisfaction of offer conditions.
Bristol-Myers Squibb Company (BMS) has responded to a comment letter from the U.S. Securities and Exchange Commission (SEC) regarding its tender offer statement for RayzeBio, Inc., initially filed on January 25, 2024. The SEC's letter, dated February 14, 2024, raised concerns about BMS's financing plans, the conditions of the offer, and the acceptance of tenders from shareholders in compliance with jurisdictional laws. BMS, along with its wholly owned subsidiary Rudolph Merger Sub Inc., has filed an amendment to the tender offer statement, addressing the SEC's comments and confirming their intention to comply with Commission rules and regulations. The amendment includes revised disclosures about the source and amount of funds, the conditions to the offer, and the acceptance of tenders from shareholders. BMS has assured the SEC that it will promptly inform RayzeBio stockholders of any developments that may affect the satisfaction of offer conditions.
百時美施貴寶公司（BMS）回應了美國證券交易委員會（SEC）關於其最初於2024年1月25日提交的RayzeBio, Inc.的要約聲明的評論信。美國證券交易委員會於2024年2月14日發出的信函對BMS的融資計劃、要約條件以及根據司法管轄法接受股東的投標表示擔憂。BMS及其全資子公司Rudolph Merger Sub Inc. 已對要約聲明提交了修正案，回應了美國證券交易委員會的評論並確認了他們遵守委員會規章制度的意向。該修正案包括對資金來源和金額、要約條件以及股東接受投標的修訂披露。BMS已向美國證券交易委員會保證，它將立即向RayzeBio股東通報任何可能影響報價條件滿意度的事態發展。
百時美施貴寶公司（BMS）回應了美國證券交易委員會（SEC）關於其最初於2024年1月25日提交的RayzeBio, Inc.的要約聲明的評論信。美國證券交易委員會於2024年2月14日發出的信函對BMS的融資計劃、要約條件以及根據司法管轄法接受股東的投標表示擔憂。BMS及其全資子公司Rudolph Merger Sub Inc. 已對要約聲明提交了修正案，回應了美國證券交易委員會的評論並確認了他們遵守委員會規章制度的意向。該修正案包括對資金來源和金額、要約條件以及股東接受投標的修訂披露。BMS已向美國證券交易委員會保證，它將立即向RayzeBio股東通報任何可能影響報價條件滿意度的事態發展。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。